scholarly journals Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer

2017 ◽  
Vol 18 (8) ◽  
pp. 940-950 ◽  
Author(s):  
Anusha-Preethi Ganesan ◽  
James Clarke ◽  
Oliver Wood ◽  
Eva M Garrido-Martin ◽  
Serena J Chee ◽  
...  
Keyword(s):  
Lung Cancer ◽  
T Cell ◽  
Human Lung ◽  
T Cell Responses ◽  
Human Lung Cancer ◽  
Cytotoxic T Cell ◽  
Cell Responses ◽  
Cytotoxic T Cell Responses

scholarly journals Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer

2014 ◽  
Vol 124 (12) ◽  
pp. 5466-5480 ◽  
Author(s):  
Evgeniy B. Eruslanov ◽  
Pratik S. Bhojnagarwala ◽  
Jon G. Quatromoni ◽  
Tom Li Stephen ◽  
Anjana Ranganathan ◽  
...  
Keyword(s):  
Lung Cancer ◽  
T Cell ◽  
Human Lung ◽  
Early Stage ◽  
T Cell Responses ◽  
Human Lung Cancer ◽  
Cell Responses ◽  
Tumor Associated Neutrophils

scholarly journals Human tumor-associated monocytes/macrophages and their regulation of T cell responses in early-stage lung cancer

2019 ◽  
Vol 11 (479) ◽  
pp. eaat1500 ◽  
Author(s):  
Sunil Singhal ◽  
Jason Stadanlick ◽  
Michael J. Annunziata ◽  
Abhishek S. Rao ◽  
Pratik S. Bhojnagarwala ◽  
...  
Keyword(s):  
Lung Cancer ◽  
T Cells ◽  
T Cell ◽  
Human Lung ◽  
Early Stage ◽  
T Cell Responses ◽  
Effector T Cells ◽  
Human Lung Cancer ◽  
Mouse Tumor ◽  
Cell Responses

Data from mouse tumor models suggest that tumor-associated monocyte/macrophage lineage cells (MMLCs) dampen antitumor immune responses. However, given the fundamental differences between mice and humans in tumor evolution, genetic heterogeneity, and immunity, the function of MMLCs might be different in human tumors, especially during early stages of disease. Here, we studied MMLCs in early-stage human lung tumors and found that they consist of a mixture of classical tissue monocytes and tumor-associated macrophages (TAMs). The TAMs coexpressed M1/M2 markers, as well as T cell coinhibitory and costimulatory receptors. Functionally, TAMs did not primarily suppress tumor-specific effector T cell responses, whereas tumor monocytes tended to be more T cell inhibitory. TAMs expressing relevant MHC class I/tumor peptide complexes were able to activate cognate effector T cells. Mechanistically, programmed death-ligand 1 (PD-L1) expressed on bystander TAMs, as opposed to PD-L1 expressed on tumor cells, did not inhibit interactions between tumor-specific T cells and tumor targets. TAM-derived PD-L1 exerted a regulatory role only during the interaction of TAMs presenting relevant peptides with cognate effector T cells and thus may limit excessive activation of T cells and protect TAMs from killing by these T cells. These results suggest that the function of TAMs as primarily immunosuppressive cells might not fully apply to early-stage human lung cancer and might explain why some patients with strong PD-L1 positivity fail to respond to PD-L1 therapy.

scholarly journals HIV mRNA Vaccines—Progress and Future Paths

Vaccines ◽  
2021 ◽  
Vol 9 (2) ◽  
pp. 134
Author(s):  
Zekun Mu ◽  
Barton F. Haynes ◽  
Derek W. Cain
Keyword(s):  
T Cell ◽  
Neutralizing Antibodies ◽  
Vaccination Strategy ◽  
T Cell Responses ◽  
Neutralizing Antibody ◽  
Cytotoxic T Cell ◽  
Therapeutic Vaccines ◽  
Cell Responses ◽  
Broadly Neutralizing Antibody ◽  
Cytotoxic T Cell Responses

The SARS-CoV-2 pandemic introduced the world to a new type of vaccine based on mRNA encapsulated in lipid nanoparticles (LNPs). Instead of delivering antigenic proteins directly, an mRNA-based vaccine relies on the host’s cells to manufacture protein immunogens which, in turn, are targets for antibody and cytotoxic T cell responses. mRNA-based vaccines have been the subject of research for over three decades as a platform to protect against or treat a variety of cancers, amyloidosis and infectious diseases. In this review, we discuss mRNA-based approaches for the generation of prophylactic and therapeutic vaccines to HIV. We examine the special immunological hurdles for a vaccine to elicit broadly neutralizing antibodies and effective T cell responses to HIV. Lastly, we outline an mRNA-based HIV vaccination strategy based on the immunobiology of broadly neutralizing antibody development.

Melanocyte-specific, cytotoxic T cell responses in vitiligo: the effective variant of melanoma immunity?

2005 ◽  
Vol 18 (4) ◽  
pp. 234-242 ◽  
Author(s):  
Silvia Garbelli ◽  
Stefania Mantovani ◽  
Belinda Palermo ◽  
Claudia Giachino
Keyword(s):  
T Cell ◽  
T Cell Responses ◽  
Cytotoxic T Cell ◽  
Cell Responses ◽  
Cytotoxic T Cell Responses

Cytotoxic T Cell Responses against Mesothelioma by Apoptotic Cell-pulsed Dendritic Cells

2004 ◽  
Vol 169 (12) ◽  
pp. 1322-1330 ◽  
Author(s):  
Frédéric Ebstein ◽  
Carole Sapede ◽  
Pierre-Joseph Royer ◽  
Marie Marcq ◽  
Catherine Ligeza-Poisson ◽  
...  
Keyword(s):  
Dendritic Cells ◽  
T Cell ◽  
Apoptotic Cell ◽  
T Cell Responses ◽  
Cytotoxic T Cell ◽  
Cell Responses ◽  
Cytotoxic T Cell Responses

Murine Cytotoxic T Cell Responses to Human Papillomavirus E7 Protein

1994 ◽  
pp. 213-218
Author(s):  
Elena Sadovnikova ◽  
Xiaojiu Zhu ◽  
Shona M. Collins ◽  
Peter Beverley ◽  
Hans J. Stauss
Keyword(s):  
Human Papillomavirus ◽  
T Cell ◽  
T Cell Responses ◽  
Cytotoxic T Cell ◽  
Cell Responses ◽  
Cytotoxic T Cell Responses
Sign in / Sign up

Export Citation Format

Share Document